MGMT and central nervous system cancer: Even many molecular characteristics of gliomas such as the combined deletion of 1p/19q, IDH1 mutations, and hypermethylation of the MGMT promoter are expected to be detected in circulating tumor cells in peripheral serum of glioma patients.